Michael R. Page, PharmD, RPh
At the American Society of Clinical Oncology (ASCO) conference in Chicago, Ill., Novartis researchers presented data from the 768-patient, 215-center PANORAMA-1 (PANobinostat ORAl in Multiple Myeloma) trial showing that its investigational drug, LBH589, improved progression-free survival by a median of 4 months among patients with relapsed or refractory multiple myeloma who had received at least 1 prior therapy.
In patients who received bortezomib and dexamethasone with placebo, progression-free survival was 37% shorter than among patients receiving LBH589 with bortezomib and dexamethasone (hazard ratio = 0.63 [95% confidence interval (CI): 0.52 to 0.76]; P <.0001). These results led the FDA to grant Novartis priority review for LBH589 in May.
To read the rest of the article, visit our sister company Specialty Pharmacy Times at http://www.specialtypharmacytimes.com/news/LBH589-Meets-Primary-End-Point-in-Phase-III-PANORAMA-1-Study
Image of the McCormick Place in Chicago courtesy of wikimedia commons